Novartis to sell off part of generics business for $1B

Swiss pharma giant Novartis will sell part of its generic drug business, Sandoz, in a deal valued at $1 billion, reports the Wall Street Journal.

Novartis plans to sell about 300 products, including Sandoz's dermatology business and generic oral solids portfolio, to Aurobindo Pharma for $900 million in cash and up to $100 million based on performance.

The deal is part of its strategy to have Sandoz double down on higher-growth areas, such as more complex generics or biosimilars.

The sale comes at a tough time for generic drugmakers, who have seen lower profits in recent years because the prices of copycat drugs continue to drop.

Novartis expects the sale to close in 2019.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars